Cancer Treatment Ups CV Risk; Therapy’s Next Big Thing; Nude Photos Settlement

Older adults treated for cancer had double the risk of cardiovascular (CV) events, including stroke, as compared with those without cancer, emphasizing the need for long-term monitoring after cancer treatment. (Cancer)

The FDA approved isatuximab (Sarclisa), in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone, for newly diagnosed, transplant-ineligible multiple myeloma.

Will peptide-drug conjugates become the “next big thing” in targeted cancer therapy? (Endpoints News)

Bristol Myers Squibb and 2seventy bio announced discontinuation of enrollment in the phase III KarMMa-9 trial of idecabtagene vicleucel (Abecma) and lenalidomide in newly diagnosed multiple myeloma with suboptimal response to transplant because of slow patient accrual.

A phase III trial of the fixed-dose combination of the LAG-3 inhibitor favezelimab and pembrolizumab (Keytruda) failed to meet the primary endpoint of overall survival in previously treated, PD-L1-positive, microsatellite stable metastatic colorectal cancer, Merck announced.

Lehigh Valley Health Network in Pennsylvania agreed to pay $65 million to settle a lawsuit after computer hackers posted nude photos of cancer patients online. (CNN)

Adding ruxolitinib (Jakafi) to standard tyrosine kinase therapy for chronic-phase chronic myeloid leukemia significantly increased the frequency of deep molecular response. (SWOG)

AstraZeneca and Daiichi Sankyo announced that the antibody-drug conjugate datopotamab deruxtecan did not meet the prespecified survival endpoint in a phase III trial of inoperable/metastatic hormone receptor-positive, HER2-low or HER2-negative breast cancer previously treated with endocrine therapy.

New HHS rules on research misconduct still do not address the root cause of the problem — the “publish-or-perish” mentality, an opinion piece argues. (STAT)

Black patients with triple-negative breast cancer may be less likely to receive immunotherapy, despite having outcomes similar to those of white patients when they do. (American Association for Cancer Research)

Please enable JavaScript to view the

comments powered by Disqus.